Goldman Sachs
SGMO

Goldman Sachs’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Goldman Sachs’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$93.2K Buy
377,287
+186,642
+98% +$74.3K ﹤0.01% 6221
2025
Q4 		$80.1K Sell
190,645
-256,209
-57% -$136K ﹤0.01% 6233
2025
Q3 		$301K Buy
446,854
+264,590
+145% +$143K ﹤0.01% 5750
2025
Q2 		$98.7K Sell
182,264
-772,975
-81% -$459K ﹤0.01% 5820
2025
Q1 		$626K Sell
955,239
-651,670
-41% -$690K ﹤0.01% 5048
2024
Q4 		$1.64M Buy
1,606,909
+1,538,428
+2,247% +$2.81M ﹤0.01% 4458
2024
Q3 		$59.3K Sell
68,481
-1,264,973
-95% -$927K ﹤0.01% 5619
2024
Q2 		$478K Buy
1,333,454
+700,826
+111% +$379K ﹤0.01% 4859
2024
Q1 		$424K Buy
632,628
+372,943
+144% +$270K ﹤0.01% 4823
2023
Q4 		$141K Sell
259,685
-1,365,238
-84% -$629K ﹤0.01% 5232
2023
Q3 		$975K Buy
1,624,923
+504,701
+45% +$540K ﹤0.01% 4289
2023
Q2 		$1.46M Buy
1,120,222
+46,085
+4% +$63K ﹤0.01% 4097
2023
Q1 		$1.89M Sell
1,074,137
-173,040
-14% -$494K ﹤0.01% 3908
2022
Q4 		$3.92M Buy
1,247,177
+53,091
+4% +$206K ﹤0.01% 3393
2022
Q3 		$5.85M Sell
1,194,086
-254,573
-18% -$1.31M ﹤0.01% 3001
2022
Q2 		$6M Buy
1,448,659
+284,772
+24% +$1.23M ﹤0.01% 2975
2022
Q1 		$6.76M Sell
1,163,887
-53,009
-4% -$315K ﹤0.01% 3060
2021
Q4 		$9.13M Sell
1,216,896
-427,428
-26% -$3.71M ﹤0.01% 2858
2021
Q3 		$14.8M Buy
1,644,324
+90,783
+6% +$897K ﹤0.01% 2349
2021
Q2 		$18.6M Sell
1,553,541
-379,921
-20% -$4.3M ﹤0.01% 2112
2021
Q1 		$24.2M Sell
1,933,462
-543,652
-22% -$7.33M 0.01% 1784
2020
Q4 		$38.7M Buy
2,477,114
+633,779
+34% +$7.42M 0.01% 1319
2020
Q3 		$17.4M Buy
1,843,335
+224,124
+14% +$2.42M ﹤0.01% 1837
2020
Q2 		$14.5M Buy
1,619,211
+223,515
+16% +$2.07M ﹤0.01% 1948
2020
Q1 		$8.89M Buy
1,395,696
+109,101
+8% +$810K ﹤0.01% 2167
2019
Q4 		$10.8M Buy
1,286,595
+22,062
+2% +$203K ﹤0.01% 2376
2019
Q3 		$11.4M Buy
1,264,533
+70,518
+6% +$791K ﹤0.01% 2218
2019
Q2 		$12.9M Sell
1,194,015
-1,826
-0.2% -$19.4K ﹤0.01% 2190
2019
Q1 		$11.4M Sell
1,195,841
-111,179
-9% -$1.14M ﹤0.01% 2307
2018
Q4 		$15M Buy
1,307,020
+198,005
+18% +$2.46M ﹤0.01% 2033
2018
Q3 		$18.8M Buy
1,109,015
+600,719
+118% +$9.13M ﹤0.01% 1970
2018
Q2 		$7.22M Sell
508,296
-190,624
-27% -$3.17M ﹤0.01% 2684
2018
Q1 		$13.3M Sell
698,920
-212,592
-23% -$4.54M ﹤0.01% 2126
2017
Q4 		$14.9M Buy
911,512
+336,107
+58% +$5M ﹤0.01% 2161
2017
Q3 		$8.63M Buy
575,405
+475,229
+474% +$5.25M ﹤0.01% 2684
2017
Q2 		$881K Buy
100,176
+34,913
+53% +$224K ﹤0.01% 4581
2017
Q1 		$339K Sell
65,263
-109,192
-63% -$438K ﹤0.01% 5362
2016
Q4 		$532K Buy
174,455
+48,819
+39% +$178K ﹤0.01% 5008
2016
Q3 		$582K Buy
125,636
+31,010
+33% +$158K ﹤0.01% 4904
2016
Q2 		$548K Buy
94,626
+26,184
+38% +$167K ﹤0.01% 4770
2016
Q1 		$414K Sell
68,442
-108,533
-61% -$652K ﹤0.01% 4943
2015
Q4 		$1.62M Sell
176,975
-829,405
-82% -$6.39M ﹤0.01% 3824
2015
Q3 		$5.68M Buy
1,006,380
+61,155
+6% +$504K ﹤0.01% 2777
2015
Q2 		$10.5M Sell
945,225
-108,218
-10% -$1.4M ﹤0.01% 2295
2015
Q1 		$16.5M Buy
1,053,443
+335,917
+47% +$5.2M 0.01% 1897
2014
Q4 		$10.9M Buy
717,526
+248,973
+53% +$3.02M ﹤0.01% 2277
2014
Q3 		$5.05M Sell
468,553
-1,427
-0.3% -$18.6K ﹤0.01% 3002
2014
Q2 		$7.18M Buy
469,980
+57,696
+14% +$830K ﹤0.01% 2671
2014
Q1 		$7.45M Sell
412,284
-1,121,506
-73% -$21.6M ﹤0.01% 2628
2013
Q4 		$21.3M Buy
1,533,790
+208,058
+16% +$2.4M 0.01% 1698
2013
Q3 		$13.9M Buy
1,325,732
+1,094,175
+473% +$10.9M 0.01% 1923
2013
Q2 		$1.81M Buy
+231,557
New +$2.02M ﹤0.01% 3820

Other funds holding SGMO

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Goldman Sachs's SGMO Position: Q1 2026 in Review

Goldman Sachs increased its SANGAMO THERAPEUTICS INC (SGMO) stake by 98% in Q1 2026, buying an estimated $74.3K and bringing the position to 377,287 shares worth $93.2K. The position accounts for ﹤0.01% of the portfolio, ranked #6221.

Goldman Sachs first reported a position in SGMO in Q2 2013 and has held it in 52 quarters since. The position peaked at $38.7M in Q4 2020. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

  • Goldman Sachs held 377,287 shares of SANGAMO THERAPEUTICS INC worth $93.2K as of Q1 2026.
  • Goldman Sachs bought 186,642 SANGAMO THERAPEUTICS INC shares in Q1 2026, an estimated $74.3K.
  • SANGAMO THERAPEUTICS INC made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #6221 holding.
  • Goldman Sachs first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and has held it in 52 quarters since.
  • Goldman Sachs's SANGAMO THERAPEUTICS INC position peaked at $38.7M in Q4 2020.
  • 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.